Evommune, Inc.
EVMN
$18.41
-$1.82-9.00%
NYSE
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -57.14% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -57.14% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -57.14% | |||
| SG&A Expenses | 7.88% | 30.74% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -18.72% | 67.68% | |||
| Operating Income | 18.72% | -300.43% | |||
| Income Before Tax | 50.46% | -422.88% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 50.46% | -422.88% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 50.46% | -422.88% | |||
| EBIT | 18.72% | -300.43% | |||
| EBITDA | 19.11% | -320.76% | |||
| EPS Basic | 94.42% | -400.85% | |||
| Normalized Basic EPS | 94.42% | -401.01% | |||
| EPS Diluted | 94.42% | -400.85% | |||
| Normalized Diluted EPS | 94.42% | -401.01% | |||
| Average Basic Shares Outstanding | 787.75% | 4.40% | |||
| Average Diluted Shares Outstanding | 787.75% | 4.40% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||